Publications by authors named "Nicole Dakoury-Dogbo"
Background: In Western Europe, North America, and Australia, large cohort collaborations have been able to estimate the short-term CD4 cell count-specific risk of AIDS or death in untreated human immunodeficiency virus (HIV)-infected adults with high CD4 cell counts. In sub-Saharan Africa, these CD4 cell count-specific estimates are scarce.
Methods: From 1996 through 2006, we followed up 2 research cohorts of HIV-infected adults in Côte d'Ivoire.
Objective: To assess the rates and determinants of mortality, loss to follow-up and immunological failure in a nongovernmental organization-implemented program of access to antiretroviral treatment in Côte d'Ivoire.
Methods: In each new treatment center, professionals were trained in HIV care, and a computerized data system was implemented. Individual patient and program level determinants of survival, loss to follow-up and immunological failure were assessed by multivariate analysis.
Objectives: To analyse the association between the presence of resistance mutations and treatment outcomes. The impact of HIV-1 drug resistance mutations in African adults on HAART has so far never been reported.
Methods: In 2004 in Abidjan, Côte d'Ivoire, 106 adults on HAART had plasma viral load measurements.
In a cohort study of women of childbearing age in Abidjan, Côte d'Ivoire, we followed 473 HIV-infected women for 1551 person-years, and found that the incidence of pregnancy and livebirth decreased with decreasing CD4 cell counts. This has consequences in terms of scaling-up strategies for highly active antiretroviral therapy (HAART). Women who need HAART will be less likely than those who do not to be recruited into prenatal care facilities.
View Article and Find Full Text PDFObjectives: To evaluate survival, morbidity, and CD4 and viral load (VL) evolution in HIV-infected adults receiving antiretroviral therapy (ART) in Côte d'Ivoire.
Methods: Since 1996, 723 HIV-infected adults have been followed up in the ANRS 1203 cohort study in Abidjan. For those patients who received ART, we describe data between ART initiation and August 2002.
Background: WHO/UNAIDS recommended that cotrimoxazole should be prescribed in Africa in HIV-infected adults with CD4 cell counts < 500 x 10 /l, while closely monitoring bacterial diseases in as many settings as possible.
Methods: Prospective cohort study, describing bacterial morbidity in adults receiving cotrimoxazole prophylaxis (960 mg daily) between April 1996 and June 2000 in Abidjan, Côte d'Ivoire.
Results: Four-hundred and forty-eight adults (median baseline CD4 cell count 251 x 10 /l) were followed for a median time of 26 months.
Article Synopsis
- HIV prevalence among outpatients in Abidjan is high at 20%, and understanding fever causes in HIV-infected individuals can enhance care in community clinics.
- A study analyzed 269 febrile episodes in HIV-positive adults, identifying bacterial infections and malaria as major causes of fever, with bacterial diseases being most prevalent across various CD4 counts.
- Early empirical antibacterial treatment reduced hospitalization duration, while deaths were mainly from atypical mycobacteriosis and acute unexplained fever, highlighting the need for improved treatment guidelines that focus on these infections.